Medicenna Therapeutics Corp.

We were thrilled to present data from two of our preclinical programs last weekend at the Promise of IL-2 Conference in Paris. Fahar Merchant, Medicenna’s President & CEO, also took part in a panel discussion titled "IL-2: The Pharma Perspective". See the press release for more details on our preclinical programs: https://lnkd.in/gajaa6TZ At this week’s H.C. Wainwright & Co., LLC Global Investor Conference in New York City, Dr. Merchant shared key updates on our pipeline of next-generation Superkines for cancer and autoimmune diseases. He emphasized the differentiated single-agent anti-tumor activity of our potential best-in-class 'non-alpha, enhanced-beta' IL-2 program, showcased in the ongoing Phase 1/2 ABILITY-1 clinical trial. We’re excited to present further monotherapy and combination data with pembrolizumab in the second half of 2024 and throughout 2025. Learn more about our programs and listen to the webcast replay here: https://lnkd.in/gh3_nH8n

We are delighted to announce our new Board Director, Mr. Karim Lalji. As a commercial executive (including ten years at Merck), he brings us deep transactional expertise, strategic vision and big-pharma partnerships $MDNA.TO $MDNAF Read more here: https://lnkd.in/gyf97CsA

We are pleased to share Medicenna President and CEO Fahar Merchant's presentation of the Company's clinical updates on MDNA11 at the Oncology Innovation Forum last month, ahead of the American Society of Clinical Oncology 2024 Meeting. MDNA11, being evaluated in the Phase 1/2 ABILITY-1 Study, is the only non-alpha beta-enhanced IL-2 immunotherapy in clinical development. MDNA11 continues to demonstrate its best-in-class potential with differentiated deep and durable single agent activity in patients with advanced solid tumors who have failed checkpoint therapy. Sachs Associates video below accompanies the presentation on MDNA11. Read the full release for more information: https://lnkd.in/dR44hYaW #Immunotherapy #Oncology #Biotech #ClinicalTrial #AdvancedTumors

Today, we were pleased to announce a $20M CAD Investment from RA Capital Management through a non-brokered private placement. “We are excited to announce the financial backing by RA Capital Management as a result of promising single-agent clinical activity of MDNA11, our differentiated IL-2 superkine,” said Dr. Fahar Merchant, President and CEO of Medicenna. “With this funding, we have strengthened our balance sheet at a time of strong momentum, demonstrated enthusiasm for our platform by attracting a prestigious investor and extended our cash runway well into 2026 enabling us to exploit the deep clinical potential of MDNA11 and our pipeline of early-stage superkines.” Not for dissemination in the United States. Full Release: https://lnkd.in/dZ79Ffx4

We presented updated monotherapy results of our #IL2 asset at the 2024 Annual Meeting of the American Association for Cancer Research #AACR2024 Updates on our MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study include: 100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2 MSI-H patients Durable stable disease (SD) in 3 melanoma patients for 6 to 18 months with concomitant tumor shrinkage Response rate and clinical benefit rate increasing to 29% and 50% (4 PR, 3 SD), respectively, MDNA11 continues to demonstrate compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=14) who have failed checkpoint inhibitor therapies MDNA11 is generally well tolerated with no dose-limiting toxicities or vascular leak syndrome reported in any of the dose escalation cohorts We look we look forward to reporting additional data at a medical conference in the first half of 2024. Read release here: https://lnkd.in/dJaR5GRs

We look forward to presenting 2 posters at the American Association for Cancer Research Annual meeting (@AACR) in San Diego on April 9! We will present a clinical update on our Phase 1/2 ABILITY-1 Study with MDNA11. In addition, we will present pre-clinical data on MDNA113. #AACR2024 #IL2

Today we announced Q3 Fiscal 2024 financial results and highlights. With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=13) that failed checkpoint inhibitor therapies, while maintaining an acceptable safety profile Tumor shrinkage was also observed in all high-dose phase-2 eligible patients with stable disease (SD). In addition to a new PR, the clinical benefit rate (PR plus SD for over 24 weeks) and tumor control rate (PR plus all SD) increased to 46% and 69%, respectively Additional monotherapy data updates and preliminary combination escalation and expansion data to be shared in H1 and H2 of 2024 Cash runway extended through multiple data readouts and into Q2 of calendar 2025 Release: https://lnkd.in/g-wfGhk8

Today we announced Q3 Fiscal 2024 financial results and highlights. With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=13) that failed checkpoint inhibitor therapies, while maintaining an acceptable safety profile Tumor shrinkage was also observed in all high-dose phase-2 eligible patients with stable disease (SD). In addition to a new PR, the clinical benefit rate (PR plus SD for over 24 weeks) and tumor control rate (PR plus all SD) increased to 46% and 69%, respectively Additional monotherapy data updates and preliminary combination escalation and expansion data to be shared in H1 and H2 of 2024 Cash runway extended through multiple data readouts and into Q2 of calendar 2025 Release: https://lnkd.in/g-wfGhk8

We are excited to announce the dosing of the first patient in the ABILITY-1 Study combining MDNA11 with Pembrolizumab. We plan to report results from both the monotherapy expansion and combination escalation and expansion arms of the Phase 2 study in H1 and H2 2024.  #IL2 #oncology #keytruda #solidtumours Please read release here: https://lnkd.in/ez2xz_bc

Today we are pleased to announce that we have initiated enrollment in the Phase 2 ABILITY study, evaluating MDNA11 with pembrolizumab in select types of #solidtumors. Read more: https://bit.ly/3vvjt4d  #cancertherapy #immunooncology #oncology #engineeredcytokines